# To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL

> **NCT02624492** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 21 (actual)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **DRUG:** BI 836826
- **DRUG:** GemOx
- **DRUG:** Rituximab
- **DRUG:** GemOx

## Key facts

- **NCT ID:** NCT02624492
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-28
- **Primary completion:** 2018-03-16
- **Final completion:** 2018-03-16
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2019-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02624492

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02624492, "To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02624492. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*